These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 34186148)
21. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021 [TBL] [Abstract][Full Text] [Related]
22. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102 [TBL] [Abstract][Full Text] [Related]
23. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332 [TBL] [Abstract][Full Text] [Related]
24. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. Hook G; Yu J; Toneff T; Kindy M; Hook V J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198 [TBL] [Abstract][Full Text] [Related]
25. Improvement of glymphatic-lymphatic drainage of beta-amyloid by focused ultrasound in Alzheimer's disease model. Lee Y; Choi Y; Park EJ; Kwon S; Kim H; Lee JY; Lee DS Sci Rep; 2020 Sep; 10(1):16144. PubMed ID: 32999351 [TBL] [Abstract][Full Text] [Related]
26. Neutrophil recruitment and leukocyte response following focused ultrasound and microbubble mediated blood-brain barrier treatments. Poon C; Pellow C; Hynynen K Theranostics; 2021; 11(4):1655-1671. PubMed ID: 33408773 [No Abstract] [Full Text] [Related]
27. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. Liao F; Hori Y; Hudry E; Bauer AQ; Jiang H; Mahan TE; Lefton KB; Zhang TJ; Dearborn JT; Kim J; Culver JP; Betensky R; Wozniak DF; Hyman BT; Holtzman DM J Neurosci; 2014 May; 34(21):7281-92. PubMed ID: 24849360 [TBL] [Abstract][Full Text] [Related]
28. Ultrasound-targeted microbubbles destruction assists dual delivery of beta-amyloid antibody and neural stem cells to restore neural function in transgenic mice of Alzheimer's disease. Zhu Q; Xu X; Chen B; Liao Y; Guan X; He Y; Cui H; Rong Y; Liu Z; Xu Y Med Phys; 2022 Mar; 49(3):1357-1367. PubMed ID: 35092698 [TBL] [Abstract][Full Text] [Related]
30. Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner. Lecordier S; Pons V; Rivest S; ElAli A Front Immunol; 2021; 12():813536. PubMed ID: 35173711 [TBL] [Abstract][Full Text] [Related]
31. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978 [TBL] [Abstract][Full Text] [Related]
32. Investigating the efficacy of a combination Aβ-targeted treatment in a mouse model of Alzheimer's disease. Liu M; Jevtic S; Markham-Coultes K; Ellens NPK; O'Reilly MA; Hynynen K; Aubert I; McLaurin J Brain Res; 2018 Jan; 1678():138-145. PubMed ID: 29066368 [TBL] [Abstract][Full Text] [Related]
33. Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism. Liu N; Liang X; Yang C; Hu S; Luo Q; Luo H Theranostics; 2022; 12(15):6646-6664. PubMed ID: 36185606 [No Abstract] [Full Text] [Related]
34. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease. Dubey S; Heinen S; Krantic S; McLaurin J; Branch DR; Hynynen K; Aubert I Proc Natl Acad Sci U S A; 2020 Dec; 117(51):32691-32700. PubMed ID: 33288687 [TBL] [Abstract][Full Text] [Related]
35. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice. Frost JL; Liu B; Rahfeld JU; Kleinschmidt M; O'Nuallain B; Le KX; Lues I; Caldarone BJ; Schilling S; Demuth HU; Lemere CA Neurobiol Aging; 2015 Dec; 36(12):3187-3199. PubMed ID: 26453001 [TBL] [Abstract][Full Text] [Related]
36. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. Aryal M; Vykhodtseva N; Zhang YZ; McDannold N J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272 [TBL] [Abstract][Full Text] [Related]
37. Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. Chuang JY; Lee CW; Shih YH; Yang T; Yu L; Kuo YM PLoS One; 2012; 7(3):e33120. PubMed ID: 22412990 [TBL] [Abstract][Full Text] [Related]
38. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice. Hoffmann T; Rahfeld JU; Schenk M; Ponath F; Makioka K; Hutter-Paier B; Lues I; Lemere CA; Schilling S Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769222 [TBL] [Abstract][Full Text] [Related]